Aptevo Q3 net loss $5.1M; cash $7.8M; initiates RAINIER trial for AML

Aptevo Therapeutics Inc.

2024-Q3 EPS reported -$5.01

Net loss of $5.1M ($0.48 per share) in Q3 2024 vs $6.3M ($22.16) in Q3 2023.
Cash and cash equivalents $7.8M as of Sept 30, 2024, down from $16.9M at Dec 31, 2023.
Initiated Phase 1b/2 RAINIER trial for mipletamig in frontline AML based on positive dose escalation data.
ALG.APV-527 Phase 1 data: 60% of evaluable patients (9/15) achieved stable disease as monotherapy.
Raised $5.75M in two financings during the quarter.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.